> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Panel To Review 3 Accelerated Approved Drugs
- URL: https://www.fdaweb.com/panel-to-review-3-accelerated-approved-drugs/
- Published: 2021-03-15T12:00:00.000Z
- Updated: 2026-09-14T16:50:49.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5148877

*Federal Register* notice: FDA has announced a 4/27-29 Oncologic Drugs Advisory Committee meeting to hear updates on certain supplemental BLAs that were granted accelerated approval and confirmatory trials have not verified clinical benefit. Panel members are scheduled to discuss Genentech’s Tecentriq (atezolizumab), Merck’s Keytruda (pembrolizumab), and Bristol-Myers Squibb’s Opdivo (nivolumab). To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2021-03-12/pdf/2021-05202.pdf?ref=fdaweb.com).